Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Renal Pelvis and Ureter Urothelial Carcinoma 1Lymphoma, AIDS-Related 1Leukemia, Plasma Cell 1Hodgkin Disease 1Adenocarcinoma, Bronchiolo-Alveolar 1Adenocarcinoma of Lung 1

Interventions

Paclitaxel 11Carboplatin 9Taxes 8Gefitinib 7Radiotherapy 5Bevacizumab 5Radiation 4Erlotinib Hydrochloride 4Cisplatin 4Gemcitabine 3Etoposide 3Docetaxel 3Radiotherapy, Conformal 2Neoadjuvant Therapy 2veliparib 1vandetanib 1pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1motesanib diphosphate 1Thalidomide 1TER 286 1Specimen Handling 1Platinum 1Nivolumab 1Magnetic Resonance Spectroscopy 1MK 2206 1Ipilimumab 1Immunoglobulin G 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Adenocarcinoma, Bronchiolo-Alveolar × pegylated granulocyte colony-stimulating factor × Clear all
NCT00334815 2026-05-26

Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 2 Active not recruiting
29 enrolled 10 charts
Thoracic

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar

Data powered by HemOnc (CC BY 4.0) Colophon âš¡